SinoMab (中国抗体) IPO - A Hard Sell
SinoMab is a Hong Kong-based biotech company with a focus on mAb-based biologics for the treatment of immunological diseases, launched its book...
532 Views
Innovent Biologics - Promising Phase I Results for Lung Cancer
In the recent 2019 World Conference on Lung Cancer held in Spain, Innovent Biologics reported preliminary results from a Phase I clinical trial on...
429 Views
Innovent Biologics Placement - Positive Newsflow but Past Deal Performance Weighs
Innovent Biologics is raising USD 314 million to fund its clinical trial in a top-up placement. We have covered the company's listing and the...
513 Views
Shanghai Henlius (复宏汉霖) IPO: Take-Aways from Peer PD-1 Sales in China
We have gathered the sales data for PD-1 products from four players in China for the first half of 2019. As its anti-PD-1 monoclonal antibody,...
528 Views
TOT Biopharm (东曜药业) IPO: Valuation of Core Product TAB008, a Bevacizumab Biosimilar
TOT Biopharm, a China-based clinical-stage biopharmaceutical company, plans to raise at least USD 100 million from its listing in its Hong Kong...
569 Views